Listing 3 - Actual negotiations

Indication:

For the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.

Indication:

In combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer at high risk of recurrence- In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

Indication:

As add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA)

Indication:

For the treatment of adult patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Indication:

Cardiomyopathy due to transthyretin-mediated amyloidosis

Indication:

For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy

Indication:

Rheumatoid Arthritis

Indication:

Multiple Indications

Indication:

Primary hyperlipidemia and cardiovascular disease

Indication:

For the treatment of adults and adolescents 12 years and older with severe alopecia areata